Last reply 4 years ago
Progression/Transition Treatment?

Hi All, Check out Dr Ben Turners talk featured on*, he’s refreshingly honest about how hard it is to spot the transition from RRMS to SPMS; he talks about active MRI lesions too, which some PPMSers can get (see below). PRMS is about to be redefined out of existence, but that probably means they can treat it like RRMS or not treat it at all- active MRI lesions seem the be the criterion for treatment. We all have our off days …

*Multiple Sclerosis Research: MS Day: Progression
18 Sep 2014
MS Day: Progression. Today Ben Turner talks about Progression Dr Ben Turner: Q &. A How can a neurologist see a transition from RRMS to SPMS in a patient if they don’t give you MRI scan? I cannot predict SPMS from the …

Pasted from <;

Multiple Sclerosis Research: What DMT would you …
14 May 2011
The latter study is based on the observations from a subgroup analysis of the Rituximab PPMS trial that showed younger patients (<51 years) and those with active MRI scans (Gd-enhancing lesions) responded to treatment; …
Multiple Sclerosis Research: Clinical Practice in the USA
11 May 2012
Current US treatment patterns emphasize MRI in MS diagnosis and subsequent treatment decisions, treatment of early disease, aggressive initial treatment of highly active MS, and close MSer monitoring. … For PPMS, responses supported diagnosis using spinal MRI (100%) and lumbar puncture (75%) and treatment initiation in patients with brain gadolinium-enhancing lesions with or without spinal cord lesions (85%); however, there was no consensus on treatment …
Multiple Sclerosis Research: PPMS and RRMS are the …
10 May 2014
“The MRI study below demonstrates that lesions on MRI in MSers with relapse-onset or primary progressive MS are identical. They interpret that these clinical sub-types as being the same disease. This supports all the other …
Clinic Speak: off-label and private prescribing in PPMS
19 May 2014
What happens if someone with PPMS who is young and has active inflammation on MRI and wants to pay for his or her own treatment? Do I say no … Subgroup analysis showed time to CDP was delayed in rituximab-treated patients aged <51 years (hazard ratio [HR] = 0.52; p = 0.010), those with gadolinium-enhancing lesions (HR = 0.41; p = 0.007), and those aged <51 years with gadolinium-enhancing lesions (HR = 0.33; p = 0.009) compared with placebo. Adverse …

Pasted from <;

Add categories

Browse categories and add by clicking on them

You can remove current categories below by clicking the ‘x’.

4 years ago

I rest my case……

I view all these… chemicals, the same. Think of your body as the environment, the meds are an introduced species, like cane toads in Queensland. You introduce the species and then its spreads through and poisons the environment and you can’t get rid of it. So you try to manage it by introducing another thing to eliminate or mitigate the first pest, then that has a negative effect of its own so you introduce something else to kill of that…. on and on until the environment crokes (toads, crokes – you’d think I sat around endlessly trying to come up with this funny sh** wouldn’t you?)

Just chasing your tail round and round and all the while getting to tired go the right way once you’ve stopped and realised it.

These are some of the originals is that right? Correct me if I’m wrong? Therefore people have been on this stuff for potentially 20 or so years and they’re still finding out about these resulting health problems, just coming to light. What does that say for your modern ‘solutions’?

I know, it’s a balancing act for all of us, the lessor of the evils we’re faced with at any given time. Actually I understand how others can view it that way. What I know is what I choose. And you know what that is.

4 years ago

Sorry my comment relates to the letter about Avonex and inteferon beta, ADD moment, a long one….

Join to reply to this post.

Become part of the community so you can chat, compare and learn from other MSers.